deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02561000

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (TRIP-PCI)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)

Sponsor: Inova Fairfax Hospital

Conditions Acute Coronary Syndrome Arterial Occlusive Diseases Arteriosclerosis Coronary Artery Disease Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases
Interventions PZ-128 Placebo
Updated 13 times since 2017 Last updated: Apr 1, 2025 Started: May 27, 2016 Primary completion: Sep 17, 2019 Completion: Sep 17, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02561000, this PHASE2 trial focuses on Acute Coronary Syndrome and Arterial Occlusive Diseases and remains completed. Sponsored by Inova Fairfax Hospital, it has been updated 13 times since 2016, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2018 · 15 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jul 2024 · 39 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – present · 14 months · monthly snapshot

Change History

13 versions recorded

  1. May 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — May 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Suspended → Completed

  2. Jul 2019 — Oct 2019 [monthly]

    Suspended PHASE2

  3. Jun 2019 — Jul 2019 [monthly]

    Suspended PHASE2

  4. May 2019 — Jun 2019 [monthly]

    Suspended PHASE2

  5. Jun 2018 — May 2019 [monthly]

    Suspended PHASE2

  6. May 2018 — Jun 2018 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  7. Feb 2017 — May 2018 [monthly]

    Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Inova Fairfax Hospital
  • National Heart, Lung, and Blood Institute (NHLBI)
  • RTI International
  • Tufts Medical Center
  • University of Massachusetts, Worcester
Data source: Tufts Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations